Home / Business and Economy / Jazz Pharma Buys Epilepsy Drug for $1.32B
Jazz Pharma Buys Epilepsy Drug for $1.32B
10 Aug
Summary
- Jazz Pharmaceuticals is acquiring Actio Biosciences for up to $1.32 billion.
- The deal adds an experimental treatment for rare KCNT1-related epilepsy.
- This inherited epilepsy form currently has no approved therapies.
Jazz Pharmaceuticals has entered into an agreement to acquire privately held Actio Biosciences in a transaction valued at up to $1.32 billion. This acquisition is set to enhance Jazz Pharmaceuticals' pipeline with ABS-1230, an investigational treatment for KCNT1-related epilepsy.
KCNT1-related epilepsy is a rare and severe inherited disorder characterized by frequent seizures and significant developmental challenges in affected children. The acquisition aims to address a critical unmet medical need, as no therapies are currently approved for this specific condition.
The deal, announced on Monday, signifies Jazz Pharmaceuticals' commitment to developing treatments for rare diseases with limited therapeutic options.
